<div id="readability-page-1"><ul><li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li></ul><p>CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Cantor Fitzgerald lifted their FY2026 earnings estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, November 11th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings per share of ($6.22) for the year, up from their prior forecast of ($6.71). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.</p><p>Several other equities analysts have also recently issued reports on CRSP. Needham &amp; Company LLC decreased their target price on shares of CRISPR Therapeutics from $81.00 to $80.00 and set a &#34;buy&#34; rating for the company in a research note on Monday. Wells Fargo &amp; Company  set a $75.00 price target on shares of CRISPR Therapeutics in a research report on Monday, October 13th. HC Wainwright  reiterated a &#34;buy&#34; rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, September 23rd. Robert W. Baird dropped their price objective on CRISPR Therapeutics from $52.00 to $44.00 and set a &#34;neutral&#34; rating on the stock in a report on Tuesday. Finally, Zacks Research upgraded shares of CRISPR Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, August 26th. Eleven equities research analysts have rated the stock with a Buy rating, eight have issued  a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and an average price target of $67.84.</p><div><p><span></span><span>Get <strong>CRISPR Therapeutics</strong> alerts:</span></p></div><ul><li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li></ul><p><b>Get Our Latest Stock Analysis on CRSP</b></p><h2>CRISPR Therapeutics Trading Down 3.1%</h2><p>Shares of CRSP stock traded down $1.60 during trading hours on Thursday, reaching $50.59. 745,808 shares of the company's stock were exchanged, compared to its average volume of 2,550,948. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $78.48. The stock's fifty day moving average price is $63.02 and its two-hundred day moving average price is $53.44. The stock has a market cap of $4.82 billion, a PE ratio of -9.09 and a beta of 1.89. </p><ul><li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li></ul><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping analysts' consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $8.74 million. </p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. SVB Wealth LLC purchased a new stake in  CRISPR Therapeutics during the first quarter valued at about $25,000.  Costello Asset Management INC bought a new stake in  CRISPR Therapeutics during the first quarter valued at approximately $27,000.  Atlantic Union Bankshares Corp bought a new position in  CRISPR Therapeutics in the second quarter valued at $33,000.  Thompson Investment Management Inc. purchased a new position in shares of  CRISPR Therapeutics during the 3rd quarter valued at about $33,000.  Finally, Optiver Holding B.V. boosted its stake in shares of  CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after purchasing an additional 210 shares in the last quarter. Hedge funds and other institutional investors own  69.20% of the company's stock. </p><h2>Insiders Place Their Bets</h2><p>In related news, General Counsel James R. Kasinger sold 1,076 shares of the firm's stock in a transaction dated Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total value of $71,661.60. Following the completion of the sale, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. This trade represents a 1.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 50,895 shares of the firm's stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares in the company, valued at approximately $17,262,789.91. This represents a 16.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 56,213 shares of company stock valued at $3,810,458. Corporate insiders own  4.30% of the company's stock. </p><h2>About CRISPR Therapeutics</h2> (Get Free Report)<p>CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than CRISPR Therapeutics</li><li>10 Best Airline Stocks to Buy</li><li>AMD to $300 Looks Easy—Here’s Why $500 Could Be Next</li><li>Where Do I Find 52-Week Highs and Lows?</li><li>$5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You </li><li>Utilities Stocks Explained – How and Why to Invest in Utilities</li><li>4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p><p>While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRSP

<p>Cantor Fitzgerald analysts have raised their FY2026 earnings estimates for CRISPR Therapeutics, predicting a smaller loss per share than previously expected. The stock has a consensus 'Hold' rating with an average price target of $67.84. Recent trading saw a 3.1% decline in stock price to $50.59. Institutional investors have been active, with significant insider trading reported. The company's recent quarterly earnings exceeded expectations, despite a negative net margin and return on equity.</p>

Equities Analysts Issue Forecasts for CRSP FY2026 Earnings